Ge Long Hui·2025-08-28 10:27Financial Performance - The company reported a revenue of RMB 3.25 billion for the six months ending June 30, 2025, representing a year-on-year decline of 3.2% [1] - Profit attributable to shareholders decreased by 22.2% to RMB 383 million during the same period, with earnings per share at RMB 0.45 [1] - The board has decided not to declare any interim dividend for the six months ending June 30, 2025 [1] Clinical Research Projects - As of June 30, 2025, the company has 409 clinical research projects ongoing domestically and 237 projects abroad [1] - Among the international projects, 194 are conducting single-region clinical trials primarily in South Korea, Australia, Southeast Asia, Europe, and the United States [1] - The company is also involved in multi-region clinical trials across the Asia-Pacific, North America, Europe, and Africa, covering therapeutic areas such as oncology, respiratory, cardiovascular, endocrine, rheumatology, infectious diseases, rare diseases, and vaccines [1] Future Strategy - The company aims to embrace regulatory changes, technological innovations, and global expansion to enhance its integrated clinical research service platform [2] - Plans include establishing dedicated business teams for specific therapeutic areas to expand client relationships with multinational and large domestic pharmaceutical companies [2] - The company seeks sustainable growth and potential acquisitions to enhance its business and operational capabilities in the U.S. and Europe, while strengthening collaborative relationships within the industry to solidify its domestic market position and increase global market share [2]